Article

Results of intratympanic dexamethasone injection as salvage treatment in idiopathic sudden hearing loss

Department of Otorhinolaryngology, Head and Neck Surgery, Pundang Jesaeng Hospital, Daejin Medical Center, Sungnam, Korea.
Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale (Impact Factor: 0.72). 04/2008; 37(2):263-8. DOI: 10.2310/7070.2008.0055
Source: PubMed

ABSTRACT To evaluate the efficacy of intratympanic (IT) dexamethasone injection as a salvage treatment in idiopathic sudden hearing loss (ISHL) patients.
A prospective study.
A secondary care hospital.
Fifty-two subjects whose pure-tone averages (PTAs) after a 2-week standard treatment were > 30 dB or worse than 10 dB from the contralateral ear were included. Thirty-four patients underwent IT dexamethasone injection and 18 patients (control) received no further treatment. Final hearing outcome was compared between the two groups.
At 2 weeks after IT dexamethasone injection, audiograms were obtained and compared between the two groups.
Sixteen patients (47.1%) in the IT dexamethasone group and 8 patients (44.4%) in the control group finally showed an improvement of 10 dB or more in PTA or a 15% or more change in speech discrimination score (p > .05). The average improvement in PTAs was 8.2 dB in the IT dexamethasone group and 3.6 dB in the control group (p = .184). Patients responsive to the initial treatment showed better final outcomes, irrespective of IT dexamethasone injection.
The present study does not support IT dexamethasone injection as a beneficial salvage treatment for ISHL patients. The true efficacy of this procedure still needs to be investigated.

1 Follower
 · 
60 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Sudden sensorineural hearing loss is usually unilateral and can be associated with tinnitus and vertigo. In most cases the cause is not identified, although various infective, vascular, and immune causes have been proposed. A careful examination is needed to exclude life threatening or treatable causes such as vascular events and malignant diseases, and patients should be referred urgently for further assessment. About half of patients completely recover, usually in about 2 weeks. Many treatments are used, including corticosteroids, antiviral drugs, and vasoactive and oxygen-based treatments. Although no treatment is proven, we recommend a short course of oral high-dose corticosteroids. There is much to learn about pathogenesis of sudden sensorineural hearing loss, and more clinical trials are needed to establish evidence-based management.
    The Lancet 04/2010; 375(9721):1203-11. DOI:10.1016/S0140-6736(09)62071-7 · 45.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Idiopathic sudden sensorineural hearing loss is an unexplained unilateral hearing loss with onset over a period of less than 72 hours, without other known otological diseases.We present a consensus on the diagnosis, treatment and follow-up of this disease, designed by AMORL, after a systematic review of the literature from 1966 to June 2010.Diagnosis of sudden sensorineural hearing loss is based on mandatory otoscopy, acoumetry, tonal audiometry, speech audiometry, and tympanometry. After clinical diagnosis is settled, and before treatment is started, a full analysis should be done and an MRI should be requested later.Treatment is based on systemic corticosteroids (orally in most cases), helped by intratympanic doses as rescue after treatment failures.Follow-up should be done at day 7, with tonal and speech audiometries, and regularly at 15, 30, and 90 days after start of therapy, and after 12 months.By consensus, results after treatment should be reported as absolute dBs recovered in pure tonal audiometry, as improvement in the recovery rate in unilateral cases, and as improvement in speech audiometry.ResumenLa sordera súbita idiopática es aquella hipoacusia neurosensorial de inicio súbito, en menos de 72 horas, sin otros antecedentes otológicos previos.Presentamos un consenso sobre el diagnóstico, tratamiento y seguimiento de la sordera súbita, surgido desde la Asociación Madrileña de ORL.Mediante revisión sistemática de la literatura sobre sordera súbita, desde 1966 hasta junio de 2010, sobre los términos MESH “(acute or sudden) hearing loss”, llegando a las siguientes sugerencias: en cuanto al diagnóstico, ante una sospecha clínica de sordera súbita, las pruebas diagnósticas que se consideran necesarias son: otoscopia, acumetría, audiometría tonal, audiometría verbal y timpanograma.Una vez hecho el diagnóstico clínico de sordera súbita, antes de comenzar el tratamiento, se solicitará una batería analítica, debiendo completarse más tarde el estudio con RM de oído interno.Se recomienda que el tratamiento de la sordera súbita esté basado fundamentalmente en los corticoides sistémicos, generalmente por vía oral, apoyados en los corticoides intratimpánicos como rescate.Respecto al seguimiento, se realizará un control a la semana del inicio del mismo, incluyendo audiometría tonal y verbal, y a los 15, 30 y 90 días del diagnóstico, y 12 meses después.Como consenso, el resultado de los tratamientos aplicados debería presentarse, tanto en cuanto a la cantidad de dBs recuperados en el umbral auditivo tonal como siguiendo la tasa de recuperación en los casos unilaterales, así como con parámetros de audiometría verbal.
    01/2011; 62(2):144–157. DOI:10.1016/S2173-5735(11)70025-4
  • [Show abstract] [Hide abstract]
    ABSTRACT: Idiopathic sudden sensorineural hearing loss is an unexplained unilateral hearing loss with onset over a period of less than 72hours, without other known otological diseases.We present a consensus on the diagnosis, treatment and follow-up of this disease, designed by AMORL, after a systematic review of the literature from 1966 to June 2010.Diagnosis of sudden sensorineural hearing loss is based on mandatory otoscopy, acoumetry, tonal audiometry, speech audiometry, and tympanometry. After clinical diagnosis is settled, and before treatment is started, a full analysis should be done and an MRI should be requested later.Treatment is based on systemic corticosteroids (orally in most cases), helped by intratympanic doses as rescue after treatment failures.Follow-up should be done at day 7, with tonal and speech audiometries, and regularly at 15, 30, and 90 days after start of therapy, and after 12 months.By consensus, results after treatment should be reported as absolute dBs recovered in pure tonal audiometry, as improvement in the recovery rate in unilateral cases, and as improvement in speech audiometry.
    Acta Otorrinolaringológica Española 03/2011; 62(2):144-157. DOI:10.1016/j.otorri.2010.09.001
Show more